Interim Report 2026
Filed with HKEX · Stock code 690 · · 78 pages · English
Uni Bio Science Group, Ltd. on 6ix
Earlier from Uni Bio Science
- Uni Bio Science Secures Approval for Recombinant Collagen Class II Medical Device and Launches 肌顏態®: Pioneering Entry into the High Growth Medical Aesthetics Market
- Uni Bio Science Announces 2022 Annual Results，Record High Turnover of HK$440.3 Million and HK$38.5 Million Profit Achieved Expanding Portfolio with New Drug Innovations and Strategic R&D Partnerships
- Interim Report 2022
- Uni Bio Science opens Hong Kong research centre,Future R&D focus in four major businesses
- 2021 Annual Results—Achieved Record-High Turnover and EGF Products Recorded Strong Rebound Successful Expansion Into Ophthalmology and Other Potential Therapeutic Areas
Later from Uni Bio Science
- Notification letter and request form
- Notification letter and reply form
- Monthly return of equity issuer on movements in securities for the month ended 30 September 2026
- Monthly return of equity issuer on movements in securities for the month ended 31 October 2026
Follow Uni Bio Science into a list and get an email when it puts out news.
Follow Uni Bio Science